1121057-69-9

Basic information

• Product Name: tert-butyl 4-(2-fluorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• Synonyms: tert-butyl 4-(2-fluorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate
• CAS NO: 1121057-69-9
• Molecular Weight: 277.339
• Mol File: 1121057-69-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(2-fluorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(2-fluorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(1121057-69-9)
• EPA Substance Registry System: tert-butyl 4-(2-fluorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate(1121057-69-9)

Safety Data

• Hazardous Substances Data: 1121057-69-9(Hazardous Substances Data)

Upstream product

• 1993-03-9 o-fluorophenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 180161-17-5 4-(2-fluorophenyl)piperidine 
• 1239205-10-7 4-(2-fluoro-phenyl)-3-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents

Epilepsy is a kind of disease with complicated pathogenesis. KCNQ (Kv7) is a voltage dependent potassium channel that is mostly associated with epilepsy and thus becomes an important target in the treatment of epilepsy. In this paper, a series of substituted piperidine derivatives targeting KCNQ were designed and synthesized by using scaffold hopping and active substructure hybridization. Compounds were evaluated by fluorescence-based thallium influx assay, Rb+ flow assay and electrophysiological patch-clamp assay. Results showed that some compounds possessed more potent potassium channel opening activity than Retigabine. More significantly, compound 11 was found to have good pharmacokinetic profiles in vivo.